Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
-10%
portes grátis
Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
Translational and Clinical Outcomes
Nagaraju, Ganji Purnachandra; Ahmad, Sarfraz
Elsevier Science & Technology
04/2022
468
Dura
Inglês
9780323992831
15 a 20 dias
1130
Descrição não disponível.
1. Clinical and safety assessment of the HCC patients2. Liver transplantation for HCC therapy3. Clinical trials for HCC in the diagnosis and therapy: An international perspective4. Recent advancements in immunotherapy interventions for the management of HCC5. Role of genetic insights and tumor microenvironment in HCC: New opportunities for gene therapy6. An Update on the treatment of hepatocellular carcinoma7. An update of image-based surveillance in HCC8. Meta-analysis of PD-1/PD-L1 inhibitors in advanced HCC9. Towards a personalized medicine approach for the treatment of HCC10. Precision medicine in the theranostics of HCC11. Immunohistology of HCC-enabled precision medicine12. Artificial Intelligence and Precision Medicine for HCC13. Genomics-Enabled Precision Medicine for HCC
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?Algae; Analogs; Anticancer; Antioxidant; Apoptosis; Bioactive compounds; Biomarkers; CTLA-4; Cancer; Cathepsin B; Cell-based therapies; Chemoembolization; Chemosensitization; Chemotherapeutics; Chemotherapy; Cirrhosis; Clinical outcomes; Clinical trials; Combination immunotherapy; Combination therapy; Curcumin; DNA methylation; Diagnosis; Drug delivery; Drug development; Drug resistance; Drugs; Exosomal miRNA; Exosomes; Extracellular vesicles; Function; Gene expression patterns; HAT; HCC; HCC signaling pathways; HDAC; Hepatic steatosis; Hepatitis; Hepatitis virus; Hepatocellular cancer; Hepatocellular carcinoma; Herbs; Histone acetylation; Histone methylation; Immune checkpoint inhibitors; Immunomodulation; Immunotherapy; Inorganic nanocarriers; Lenvatinib; Liver; Liver cancer; Liver transplant; Long noncoding RNAs; Medical treatment; Metastasis; MicroRNA; Microorganisms; Molecular target therapy; Monoclonal antibodies; NAFLD; NASH; Nanocarriers; Nanoformulations; Nanomedicine; Nanoparticles; Nanotechnology; Nanotheranostics; Nonalcoholic fatty liver disease; Organic nanocarriers; Outcome measures; PD-1 receptor; PD-L1/ligand to PD-1; Pathology; Pharmacogenetics; Phytochemicals; Phytoconstituents; Plant-based drugs; Plants; Precision medicine; Prognosis; Quality-of-life; Response rates; Resveratrol; Risk factors; Secondary metabolites; Signaling pathways; Small molecules; Sorafenib; Stilbenoid; Structure; Surveillance; Survival outcomes; Systemic treatment; Targeted treatment; Therapeutic outcomes; Therapeutic targets; Therapy; Tumor; Tumor markers; Tumor progression
1. Clinical and safety assessment of the HCC patients2. Liver transplantation for HCC therapy3. Clinical trials for HCC in the diagnosis and therapy: An international perspective4. Recent advancements in immunotherapy interventions for the management of HCC5. Role of genetic insights and tumor microenvironment in HCC: New opportunities for gene therapy6. An Update on the treatment of hepatocellular carcinoma7. An update of image-based surveillance in HCC8. Meta-analysis of PD-1/PD-L1 inhibitors in advanced HCC9. Towards a personalized medicine approach for the treatment of HCC10. Precision medicine in the theranostics of HCC11. Immunohistology of HCC-enabled precision medicine12. Artificial Intelligence and Precision Medicine for HCC13. Genomics-Enabled Precision Medicine for HCC
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?Algae; Analogs; Anticancer; Antioxidant; Apoptosis; Bioactive compounds; Biomarkers; CTLA-4; Cancer; Cathepsin B; Cell-based therapies; Chemoembolization; Chemosensitization; Chemotherapeutics; Chemotherapy; Cirrhosis; Clinical outcomes; Clinical trials; Combination immunotherapy; Combination therapy; Curcumin; DNA methylation; Diagnosis; Drug delivery; Drug development; Drug resistance; Drugs; Exosomal miRNA; Exosomes; Extracellular vesicles; Function; Gene expression patterns; HAT; HCC; HCC signaling pathways; HDAC; Hepatic steatosis; Hepatitis; Hepatitis virus; Hepatocellular cancer; Hepatocellular carcinoma; Herbs; Histone acetylation; Histone methylation; Immune checkpoint inhibitors; Immunomodulation; Immunotherapy; Inorganic nanocarriers; Lenvatinib; Liver; Liver cancer; Liver transplant; Long noncoding RNAs; Medical treatment; Metastasis; MicroRNA; Microorganisms; Molecular target therapy; Monoclonal antibodies; NAFLD; NASH; Nanocarriers; Nanoformulations; Nanomedicine; Nanoparticles; Nanotechnology; Nanotheranostics; Nonalcoholic fatty liver disease; Organic nanocarriers; Outcome measures; PD-1 receptor; PD-L1/ligand to PD-1; Pathology; Pharmacogenetics; Phytochemicals; Phytoconstituents; Plant-based drugs; Plants; Precision medicine; Prognosis; Quality-of-life; Response rates; Resveratrol; Risk factors; Secondary metabolites; Signaling pathways; Small molecules; Sorafenib; Stilbenoid; Structure; Surveillance; Survival outcomes; Systemic treatment; Targeted treatment; Therapeutic outcomes; Therapeutic targets; Therapy; Tumor; Tumor markers; Tumor progression
